Dec 2025 $1 M No. 5 Under $2 million 7
DMC Biotechnologies, Inc.: Raise no. 5, Dec 2025 × Investors in this round 7 investors had bought by the notice of Dec 30, 2025: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jim Flatt · Executive Officer, Director Josh Yelen · Executive Officer Alastair Cooper · Director Doug Cameron · Director Josko Bobanovic · Director K'Lynne Johnson · Director Matthew Lipscomb · Director Rob van der Meij · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jim Flatt, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 30, 2025. Read the notice at the SEC .
equity, debt, options SEC Apr 2025 $5 M No. 4 $2 to $10 million 9
DMC Biotechnologies, Inc.: Raise no. 4, Apr 2025 × Investors in this round 9 investors had bought by the notice of Apr 23, 2025: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jim Flatt · Executive Officer, Director Josh Yelen · Executive Officer Alastair Cooper · Director Doug Cameron · Director Josko Bobanovic · Director K'Lynne Johnson · Director Matthew Lipscomb · Director Rob van der Meij · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jim Flatt, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 23, 2025. Read the notice at the SEC .
equity, debt, options SEC Nov 2021 $34 M No. 3 $10 to $50 million 12
DMC Biotechnologies, Inc.: Raise no. 3, Nov 2021 × Investors in this round 12 investors had bought by the notice of Dec 10, 2021: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $34 M of $44 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Matthew Lipscomb · Executive Officer, Director Alastair D. Cooper · Director Carolyn D. Fritz · Director Doug D. Cameron · Director Josko D. Bobanovic · Director Michael D. Lynch · Director Rob D. van der Meij · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Offering Amount and Total Amount Sold includes equity issued upon the conversion of outstanding principal and interest of convertible promissory notes.”Signed by Matthew Lipscomb, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2021. Read the notice at the SEC .
equity SEC Jun 2019 $5 M No. 2 $2 to $10 million 3
DMC Biotechnologies, Inc.: Raise no. 2, Jun 2019 × Investors in this round 3 investors had bought by the notice of Jun 27, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $12 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Matthew Lipscomb · Executive Officer, Director Carolyn D. Fritz · Director Josko D. Bobanovic · Director Michael D. Lynch · Director Rob D. van der Meij · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Matthew Lipscomb, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 27, 2019. Read the notice at the SEC .
equity SEC Jan 2018 $3 M No. 1 $2 to $10 million 3
DMC Biotechnologies, Inc.: Raise no. 1, Jan 2018 × Investors in this round 3 investors had bought by the notice of Mar 15, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Matthew L. Lipscomb · Executive Officer, Director Carolyn D. Fritz · Director Michael D. Lynch · Director Rob D. van der Meij · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offer and Sale of Series Seed Preferred Stock and Series Seed Preferred Stock Warrants (and the shares issuable thereunder)”Signed by Matthew L. Lipscomb, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 15, 2019. Read the notice at the SEC .
equity, options SEC